Advertisement

Related Videos

Deborah Collyar: What's In It for Patients?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Amit Sanyal, MD: A Clinician’s Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Advertisement

Advertisement




Sep
28
Today In Oncology
Adding Targeted Immunotherapy to Pembrolizumab in Recurrent or Metastatic HPV16-Positive Head and Neck Squamous Cell Carcinoma
SRS Is a Reasonable Option for Patients With SCLC and Brain Metastases
Fractionated SRS Approach Improves Outcomes for Patients With Resected Large Brain Metastases
FDA Advisory Committee Votes in Favor of Approval of Multi-Cancer Early Detection Test
Bivalent CAR T-Cell Therapy Shows No Delayed Toxicity and Promising Survival in Recurrent Glioblastoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo